{"schema_version":"1.0","type":"article","title":"The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era","url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.md","lang":"en","date":"2026-06-09","publish_at":"2026-06-09T10:30:00+08:00","updated_at":"2026-06-09","category":"商業分析系列","topic":"BD / 授權","tags":["BD and Licensing","Radiopharma","Business development","Biotech business analysis","Drug development"],"summary":"Curium's rumored interest in Lantheus is best read as a bid for nuclear-medicine infrastructure: isotope access, hospital channels, imaging workflow, and radiopharma commercialization depth.","key_points":[],"facts":[],"sections":["01｜Lantheus is valuable, not just a prostate cancer PET drug","02｜The focus of PYLARIFY TruVu is not the new name, but the industrialization capabilities of radiopharmaceuticals","03｜Curium buys Lantheus. What it buys is not a product, but an import from the US hospital.","04｜Nuclear drug mergers and acquisitions are not single-point events, but an arms race among large pharmaceutical companies.","05｜Why nuclear weapons now? Because the business model has been verified, but the supply bottleneck has not yet been solved","06｜Taiwanese investors should not just ask “Which is a nuclear medicine concept stock?”","07｜What Taiwanese companies should really be re-evaluated is not just whether they have nuclear weapons, but whether they have \"scalable capabilities.\"","Conclusion｜Nuclear medicine is not just a story, it will eventually return to the supply chain and clinical site"],"references":[{"title":"Fierce Pharma","source":"Lantheus considers potential $7B Curium buyout proposal","date":"","url":""},{"title":"Lantheus","source":"Q1 2026 Financial Results and Business Update","date":"","url":""},{"title":"Lantheus","source":"FDA Approval of PYLARIFY TruVu","date":"","url":""},{"title":"Novartis","source":"Product Sales, Full Year 2024","date":"","url":""}],"images":[{"alt":"Radiopharma Is a Platform Game","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-radiopharma-acquisition-en/figure-01.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/curium-lantheus-radiopharma-acquisition-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-09）。The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era。https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-09-curium-lantheus-radiopharma-acquisition.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}